Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Novome Biotechnologies, Inc. is a clinical-stage biotechnology company focused on developing engineered microbial medicines. They are pioneering the use of genetically engineered microbial medicines (GEMMs) – commensal bacteria engineered to perform specific therapeutic functions within the human gut. Their lead program targets enteric hyperoxaluria, a condition characterized by excessive oxalate absorption leading to kidney stones and potentially kidney failure. Novome aims to provide novel, oral therapies for chronic diseases with significant unmet medical needs by harnessing the power of the gut microbiome.
The Emeryville headquarters serves as the central hub for Novome's research and development, laboratory operations, clinical development, and corporate administration.
Located within a modern biotech facility, likely equipped with state-of-the-art laboratories for microbial engineering, fermentation, and analytical testing.
As a cutting-edge biotech firm, the work culture is likely highly collaborative, innovative, science-driven, and fast-paced, with a strong emphasis on problem-solving and achieving breakthroughs in microbial therapeutics.
The headquarters is strategically located in a leading U.S. biotech cluster, facilitating access to talent, research institutions, and potential collaborators, which is crucial for their pioneering work.
Novome Biotechnologies currently operates primarily from its headquarters in Emeryville, California, USA. While their direct physical presence is U.S.-based, their research and development efforts for novel therapeutics have the potential for global impact, and they may engage in international clinical trials or collaborations as their programs advance.
5940 Horton St, Suite 350
Emeryville
CA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Novome Biotechnologies' leadership includes:
Novome Biotechnologies has been backed by several prominent investors over the years, including:
In January 2024, Novome Biotechnologies announced the appointment of Rebecca Buckley, M.D., as Chief Medical Officer.
Discover the tools Novome Biotechnologies uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Novome Biotechnologies, Inc. likely utilizes common professional email formats. The most probable format is the first initial followed by the last name.
[first_initial][last]@novomebio.com
Format
jdoe@novomebio.com
Example
80%
Success rate
Business Wire • January 9, 2024
Novome Biotechnologies announced the appointment of Rebecca Buckley, M.D., as Chief Medical Officer. Dr. Buckley will oversee the company's clinical development strategy and execution for its pipeline of genetically engineered microbial medicines....more
Business Wire • May 22, 2023
Novome presented positive topline results from its Phase 1, open-label study of NB1001 in healthy volunteers. The study demonstrated that NB1001 was well-tolerated and achieved pharmacodynamic proof-of-concept by significantly reducing urinary oxalate levels....more
PR Newswire • September 7, 2022
Novome Biotechnologies, Inc. announced the successful close of a $43.5 million Series B financing round. The round was co-led by new investor Teamworthy Ventures and existing investor DCVC Bio, with participation from other new and existing investors including 5AM Ventures, Alexandria Venture Investments, Catalio Capital Management, and SymBiosis....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Novome Biotechnologies, are just a search away.